Clinical Policy: Infectious Disease Agents: Antifungals for Onychomycosis & Systemic Infections
Reference Number: OH.PHAR.PPA.70
Effective Date: 01/01/2020
Last Review Date: N/A
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description:

**INFECTIOUS DISEASE AGENTS: AGENTS FOR ONYCHOMYCOSIS**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRIFULVIN®V tablets (griseofulvin, microsize)</td>
<td>ITRACONAZOLE (generic of Sporanox®)</td>
</tr>
<tr>
<td>GRISEOFULVIN suspension (generic of Grifulvin®V)</td>
<td>LAMISIL Granules (terbinafine)</td>
</tr>
<tr>
<td>GRIS-PEG® (griseofulvin, ultramicrosize)</td>
<td>ONMEL® (itraconazole)</td>
</tr>
<tr>
<td>TERBINAFINE (generic of Lamisil®)</td>
<td>SPORANOX® 100mg/10ml oral solution (itraconazole)</td>
</tr>
</tbody>
</table>

**INFECTIOUS DISEASE AGENTS: AGENTS FOR SYSTEMIC INFECTIONS**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUCONAZOLE (generic of Diflucan®)</td>
<td>CRESEMBA® (isavuconazonium)</td>
</tr>
<tr>
<td>FLUCONAZOLE suspension (generic of Diflucan®)</td>
<td>ITRACONAZOLE capsules (generic of Sporanox®)</td>
</tr>
<tr>
<td>FLUCYTOSINE (generic of Ancobon®)</td>
<td>NOXAFIL® (posaconazole)</td>
</tr>
<tr>
<td>KETOCONAZOLE (generic of Nizoral®)</td>
<td>ORAVIG® (miconazole)</td>
</tr>
<tr>
<td></td>
<td>SPORANOX® 100mg/10ml oral solution (itraconazole)</td>
</tr>
<tr>
<td></td>
<td>VORICONAZOLE (generic of Vfend®)</td>
</tr>
<tr>
<td></td>
<td>TOLSURA (itraconazole)</td>
</tr>
</tbody>
</table>

**FDA Approved Indication(s):**
Antifungals are indicated for the treatment of:
- aspergillosis
- blastomycosis
- bone and joint infections
- candidemia
- candidiasis
- candidiasis prophylaxis
- candiduria
- cryptococcal meningitis
- cryptococcosis
- cystitis
Infectious Disease Agents: Antifungals for Onychomycosis & Infections

- endocarditis
- esophageal candidiasis
- histoplasmosis
- intraabdominal abscess
- intraabdominal infections
- meningitis
- mucormycosis
- onychomycosis
- oropharyngeal candidiasis (thrush)
- peritonitis
- pneumonia
- pyelonephritis
- sinusitis
- skin and skin structure infections
- tinea barbae
- tinea capitis
- tinea corporis
- tinea cruris
- tinea pedis
- urinary tract infection (UTI)
- vulvovaginal candidiasis

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Buckeye Health Plan, an affiliate of Centene Corporation®, that Sporanox, Lamisil Granules, Onmel, Cresemba, Noxafil, Oravig, Vfend, and Tolsura are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. For Sporanox, Lamisil Granules, Onmel, Noxafil, Oravig, Vfend, and Tolsura (must meet all):
      1. FDA-approved or supported by standard pharmacopeias;
      2. The member meets one of the following (a, b, or c):
         a. Documentation that the member has a serious illness that causes them to be immunocompromised [i.e. AIDS, cancer, organ (solid or non-solid) transplant];
         b. Documentation that there have been therapeutic failures to no less than a 7 day trial of at least one medication not requiring prior approval UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
            • Allergies to all medications not requiring prior approval.
            • Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
Infectious Disease Agents: Antifungals for Onychomycosis & Infections

- History of unacceptable/toxic side effects to medications not requiring prior approval.
  
c. Documentation that the member is completing a course of therapy with a medication which was initiated in the hospital OR if the member has just become Medicaid eligible and is already on course of treatment.

NOTE: An off-label use may be approvable for a medication (such as Nizoral) for advanced prostate cancer or for Cushing’s Syndrome when standard treatments have failed.

Approval duration: For the duration of the prescription (up to 180 days).

B. For Cresemba (isavuconazonium) (must meet all):
   1. Diagnosis of invasive aspergillosis or invasive mucormycosis;
   2. Age ≥ 18 years;
   3. Prescribed by or in consultation with an infectious disease specialist;
   4. The member meets one of the following (a, b, or c):
      a. Documentation that the member has a serious illness that causes them to be immunocompromised [i.e. AIDS, cancer, organ (solid or non-solid) transplant];
      b. Documentation that there have been therapeutic failures to no less than a 7 day trial of at least one medication not requiring prior approval UNLESS there is a reason the member cannot be changed to a preferred medication. Acceptable reasons include:
         - Allergies to all medications not requiring prior approval.
         - Contraindication to or drug-to-drug interaction with medications not requiring prior approval.
         - History of unacceptable/toxic side effects to medications not requiring prior approval.
      c. Documentation that the member is completing a course of therapy with a medication which was initiated in the hospital OR if the member has just become Medicaid eligible and is already on course of treatment.

Approval duration: For the duration of the prescription (up to 180 days).

C. Other diagnoses/indications:
   1. There are no pharmacy and therapeutic committee approved off-label use criteria for the diagnosis;
   2. Use is supported by one of the following (a, b, or c):
      a. The National Comprehensive Cancer Network (NCCN) Drug Information and Biologics Compendium level of evidence 1 or 2A;
      b. Evidence from at least two high-quality, published studies in reputable peer-reviewed journals or evidence-based clinical practice guidelines that provide all of the following (i – iv):
         i. Adequate representation of the member’s clinical characteristics, age, and diagnosis;
         ii. Adequate representation of the prescribed drug regimen;
         iii. Clinically meaningful outcomes as a result of the drug therapy in question;
         iv. Appropriate experimental design and method to address research questions;
      c. Micromedex DrugDex® with strength of recommendation Class I, IIa, or IIb;
CLINICAL POLICY
Infectious Disease Agents: Antifungals for Onychomycosis & Infections

3. Prescribed by or in consultation with an appropriate specialist for the diagnosis;
4. Failure of an adequate trial of at least two FDA-approved drugs for the indication and/or drugs that are considered the standard of care, when such agents exist for the same indication at maximum indicated doses, unless no such drugs exist, at maximum indicated doses, unless contraindicated or clinically significant adverse effect are experienced;
5. Dosing regimen and duration are within dosing guidelines recommended by clinical practice guidelines and/or medical literature.

Approval duration: For the duration of the prescription (up to 180 days).

II. Diagnoses/Indications for which coverage is NOT authorized:
Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 for Medicaid or evidence of coverage documents.

III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
ER: Extended Release
FDA: Food and Drug Administration
PA: Prior Authorization
UTI: Urinary Tract Infection

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>griseofulvin microsize tablets</td>
<td><strong>Tinea corporis, tinea cruris, tinea capitis, tinea barbae</strong></td>
<td>1 g daily</td>
</tr>
<tr>
<td>(Grifulvin V)</td>
<td>500 mg given either once daily or in 2 to 4 divided doses per day</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Tinea pedis or tinea unguium (onychomycosis)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>750 to 1000 mg given either once daily or in 2 to 4 divided doses</td>
<td></td>
</tr>
<tr>
<td>griseofulvin suspension (Grifulvin V)</td>
<td><strong>Tinea corporis, tinea cruris, tinea capitis, tinea barbae</strong></td>
<td>1 g daily</td>
</tr>
<tr>
<td></td>
<td>500 mg given either once daily or in 2 to 4 divided doses per day</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Tinea pedis or tinea unguium (onychomycosis)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>750 to 1000 mg given either once daily or in 2 to 4 divided doses</td>
<td></td>
</tr>
<tr>
<td>Drug Name</td>
<td>Dosing Regimen</td>
<td>Dose Limit/Maximum Dose</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>griseofulvin ultramicropose tablets (GrisPEG)</td>
<td><strong>Tinea corporis, tinea cruris, tinea capitis, tinea barbae</strong>&lt;br&gt;300 to 375 mg given either once daily or in 2 to 4 divided doses per day&lt;br&gt;&lt;br&gt;<strong>Tinea pedis or tinea unguium (onychomycosis)</strong>&lt;br&gt;660 to 750 mg given either once daily or in 2 to 4 divided doses</td>
<td>750 mg daily</td>
</tr>
<tr>
<td>terbinafine (Lamisil)</td>
<td><strong>Onychomycosis</strong>&lt;br&gt;250 mg once daily. Treatment should continue for 6 weeks for treatment of fingernails, and 12 weeks for treatment of toenails.</td>
<td>250 mg daily</td>
</tr>
<tr>
<td>fluconazole (Diflucan)</td>
<td><strong>Candidemia and invasive (non-CNS) candidiasis</strong>&lt;br&gt;800 mg (12 mg/kg) once, then 400 mg (6 mg/kg) once daily&lt;br&gt;&lt;br&gt;<strong>Oropharyngeal candidiasis (thrush)</strong>&lt;br&gt;200 mg once, then 100 mg once daily for 7 to 14 days&lt;br&gt;&lt;br&gt;<strong>Esophageal candidiasis</strong>&lt;br&gt;200 mg once, then 100 mg once daily. Alternately, 200 to 400 mg (3 to 6 mg/kg/dose) once daily. Treat for 14 to 21 days and for at least 2 weeks after the resolution of symptoms.&lt;br&gt;&lt;br&gt;<strong>Vulvovaginal candidiasis (VVC)</strong>&lt;br&gt;150 mg as a single dose</td>
<td>400 mg/day. However, doses up to 12 mg/kg/day, not to exceed 800 mg/day have been recommended for severe infections.</td>
</tr>
<tr>
<td>flucytosine (Ancobon)</td>
<td><strong>Candidemia and disseminated (non-CNS) candidiasis</strong>&lt;br&gt;50 to 150 mg/kg/day in divided doses every 6 hours in combination with amphotericin B.&lt;br&gt;&lt;br&gt;<strong>Urinary tract infection (UTI), including symptomatic cystitis, caused by Candida</strong>&lt;br&gt;25 mg/kg/dose 4 times daily, with or without amphotericin B.</td>
<td>150 mg/kg/day</td>
</tr>
</tbody>
</table>
### CLINICAL POLICY
Infectious Disease Agents: Antifungals for Onychomycosis & Infections

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
</table>
| flucytosine (Ancobon) - continued | **Pyelonephritis caused by Candida** 5 mg/kg/dose 4 times daily for 2 weeks, with or without amphotericin B.  
**Cryptococcosis** 50 to 150 mg/kg/day in divided doses every 6 hours, or alternately, an initial dosage of 25 mg/kg/dose 4 times daily in combination with amphotericin B or fluconazole. | 150 mg/kg/day |
| ketoconazole (Nizoral)      | **Chromomycosis** 200 mg once daily. Serious infection may require 400 mg once daily.  
**Coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis** 200 to 400 mg once daily. For coccidioidomycosis, 400 mg once daily is recommended.  
**Blastomycosis** 200 to 400 mg once daily. | 400 mg/day |

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

### Appendix C: Contraindications/Boxed Warnings
- **Contraindication(s):**
  - Azole Antifungal Hypersensitivity
  - Hepatic Disease
  - Hepatitis
  - Milk Protein Hypersensitivity
  - Porphyria
  - Pregnancy
  - Short QT Syndrome
- **Boxed warning(s):**
  - Bone Marrow Suppression
  - Heart Failure
  - Hepatotoxicity
  - QT Prolongation
  - Renal Impairment
  - Ventricular Dysfunction

### IV. Dosage and Administration
- Varies by drug product. See FDA approved dosing and administration AND Appendix B.
Infectious Disease Agents: Antifungals for Onychomycosis & Infections

V. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cresemba</td>
<td>Capsules: 186 mg</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>Oral suspension: 10 mg/mL, 40 mg/mL</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>Tablets: 50 mg, 100 mg, 150 mg, 200 mg</td>
</tr>
<tr>
<td>Flucytosine</td>
<td>Capsules: 250 mg, 500 mg</td>
</tr>
<tr>
<td>Griseofulvin Microsize</td>
<td>Oral suspension: 125 mg/5 mL</td>
</tr>
<tr>
<td>Griseofulvin Microsize</td>
<td>Tablets: 500 mg</td>
</tr>
<tr>
<td>Gris-PEG</td>
<td>Tablets: 250 mg</td>
</tr>
<tr>
<td>Griseofulvin Ultramicrosize</td>
<td>Tablets: 125 mg, 250 mg</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Capsules: 100 mg</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Oral solution: 10 mg/mL</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Tablets: 200 mg</td>
</tr>
<tr>
<td>Noxafil</td>
<td>Oral suspension: 200 mg/5 mL</td>
</tr>
<tr>
<td>Onmel</td>
<td>Tablets: 200 mg</td>
</tr>
<tr>
<td>Oravig</td>
<td>Buccal Tablets: 50 mg</td>
</tr>
<tr>
<td>Posaconazole</td>
<td>Tablets (Delayed-Release): 100 mg</td>
</tr>
<tr>
<td>Terbinafine</td>
<td>Tablets: 250 mg</td>
</tr>
<tr>
<td>Tolsura</td>
<td>Capsules: 65 mg</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>Oral suspension: 40 mg/mL</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>Tablets: 50 mg, 200 mg</td>
</tr>
</tbody>
</table>

VI. References

- Cresemba (isavuconazonium) [package insert]. Northbrook, IL; Astellas Pharma Inc.; Revised 04/2018.

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy created.</td>
<td>10.19</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical
Infectious Disease Agents: Antifungals for Onychomycosis & Infections

policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.